Want to see AARD full AI Analyst Report?
AARD Stock Chart & Stats
$6.32
$0.37(5.85%)
At close: 4:00 PM EDT
$6.32
$0.37(5.85%)
Day’s Range― - ―
52-Week Range$3.35 - $17.94
Previous Close$6.69
Volume70.38K
Average Volume (3M)382.31K
Market Cap
$144.44M
Enterprise Value-$8.62
Total Cash (Recent Filing)$91.20M
Total Debt (Recent Filing)$336.00K
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Aug 19, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding21,884,157
10 Day Avg. Volume240,671
30 Day Avg. Volume382,312
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.20Price Target Upside-17.72% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-3.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityVery low debt and materially positive equity provide durable financial flexibility, lowering bankruptcy risk and enabling the company to fund R&D or restructure without costly debt financing. This balance-sheet strength helps absorb near-term losses and supports strategic options over the next 2–6 months.
Management Retention IncentivesRetention packages for key finance and clinical leaders reduce execution risk during a critical regulatory period. Maintaining institutional knowledge and clinical leadership improves the company's ability to respond to the FDA hold and to manage complex data reviews and regulatory interactions reliably over months.
Cash Runway Into Mid-2027A reported cash position that funds operations into mid-2027 provides a measurable runway to unblind data, engage regulators, and pursue next steps without immediate dilution. This runway materially reduces short-term liquidity pressure and enables strategic decision making over the coming quarters.
Bears Say
Pre-revenue With Rapidly Widening LossesBeing pre-revenue while losses accelerate signals that the business model depends entirely on successful clinical outcomes or external financing. Persistent negative operating results increase funding needs and dilution risk; without a commercial product, sustainable profitability remains distant absent structural change.
FDA Full Clinical Hold On Lead ProgramA full clinical hold on the flagship asset is a material structural setback: it stops pivotal development, creates regulatory uncertainty, and may require additional studies or data analyses. This elevates program risk, delays any potential revenue timeline, and increases required capital to reach approval.
Escalating Cash Burn And Negative Operating Cash FlowRapidly increasing operating cash outflows reflect rising trial and development costs and are consuming equity despite low debt. Sustained negative free cash flow forces recurring capital raises or cost reductions, constraining strategic optionality and increasing dilution risk absent revenue or partnerships.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $3.35 and its highest was $17.94 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $144.44M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 16 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.877 by -$0.113.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Overvalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.87.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,884,157 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.877. Following the earnings report the stock price went down -4.924%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.20 (-17.72% Downside)
$5.20 (-17.72% Downside)
Blogger Sentiment
Neutral
AARD Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.21%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$5.20
▼(-17.72% Downside)
Technical Analysis
Ownership Overview
14.33% Insiders
4.47% Mutual Funds
0.06% Other Institutional Investors
77.74% Public Companies and
Individual Investors